Mesenchymal stem cell therapy and Alzheimer's disease: current status and future perspectives

J Kim, Y Lee, S Lee, K Kim, M Song…�- Journal of Alzheimer's�…, 2020 - content.iospress.com
J Kim, Y Lee, S Lee, K Kim, M Song, J Lee
Journal of Alzheimer's Disease, 2020content.iospress.com
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease
worldwide, but its cause remains unclear. Although a few drugs can provide temporary and
partial relief of symptoms in some patients, no curative treatment is available. Therefore,
attention has been focused on research using stem cells to treat AD. Among stem cells,
mesenchymal stem cells (MSCs) have been used to treat the related pathologies in animal
models of AD, and other neurodegenerative disease. This review describes latest research�…
Abstract
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease worldwide, but its cause remains unclear. Although a few drugs can provide temporary and partial relief of symptoms in some patients, no curative treatment is available. Therefore, attention has been focused on research using stem cells to treat AD. Among stem cells, mesenchymal stem cells (MSCs) have been used to treat the related pathologies in animal models of AD, and other neurodegenerative disease. This review describes latest research trends on the use of MSC-based therapies in AD and its action of mechanism. MSCs have several beneficial effects. They would be specified as the reduction of neuroinflammation, the elimination of amyloid-�, neurofibrillary tangles, and abnormal protein degradation, the promotion of autophagy-associated and blood-brain barrier recoveries, the upregulation of acetylcholine levels, improved cognition, and the recovery of mitochondrial transport. Therefore, this review describes the latest research trends in MSC-based therapy for AD by demonstrating the importance of MSC-based therapy and understanding of its mechanisms in AD and discusses the limitations and perspectives of stem cell therapy in AD.
content.iospress.com